ICU Medical (NASDAQ:ICUI) Shares Unloaded Rep. Josh Gottheimer

Representative Josh Gottheimer (D-New Jersey) recently sold shares of ICU Medical, Inc. NASDAQ: ICUI. In a filing disclosed on November 06th, the Representative disclosed that they had sold between $1,001 and $15,000 in ICU Medical stock on October 31st. The trade occurred in the Representative's "MORGAN STANLEY - SELECT UMA ACCOUNT # 1" account.

Representative Josh Gottheimer also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Texas Capital Bancshares NASDAQ: TCBI on 10/31/2024.
• Sold $1,001 - $15,000 in shares of ITT NYSE: ITT on 10/31/2024.
• Sold $1,001 - $15,000 in shares of Stifel Financial NYSE: SF on 10/31/2024.
• Sold $1,001 - $15,000 in shares of AppFolio NASDAQ: APPF on 10/31/2024.
• Purchased $1,001 - $15,000 in shares of Gates Industrial NYSE: GTES on 10/31/2024.
• Purchased $1,001 - $15,000 in shares of Techtronic Industries OTCMKTS: TTNDY on 10/29/2024.
• Purchased $1,001 - $15,000 in shares of Techtronic Industries OTCMKTS: TTNDY on 10/28/2024.
• Purchased $1,001 - $15,000 in shares of Disco OTCMKTS: DSCSY on 10/28/2024.
• Purchased $1,001 - $15,000 in shares of Enerpac Tool Group NYSE: EPAC on 10/25/2024.
• Purchased $1,001 - $15,000 in shares of Disco OTCMKTS: DSCSY on 10/25/2024.

ICU Medical Stock Performance

Shares of ICUI stock traded down $1.76 during trading on Friday, reaching $176.79. The company had a trading volume of 258,159 shares, compared to its average volume of 273,344. The firm's 50 day simple moving average is $175.07 and its two-hundred day simple moving average is $139.41. ICU Medical, Inc. has a one year low of $78.28 and a one year high of $188.53. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.41 and a quick ratio of 1.08. The company has a market capitalization of $4.32 billion, a PE ratio of -60.54 and a beta of 0.66.

ICU Medical (NASDAQ:ICUI - Get Free Report) last posted its earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.56. ICU Medical had a positive return on equity of 5.01% and a negative net margin of 3.07%. The firm had revenue of $596.50 million during the quarter, compared to analyst estimates of $556.64 million. During the same period in the previous year, the company earned $1.58 EPS. The company's revenue for the quarter was up 8.6% on a year-over-year basis. Sell-side analysts forecast that ICU Medical, Inc. will post 3.81 earnings per share for the current year.

Institutional Trading of ICU Medical

Institutional investors and hedge funds have recently modified their holdings of the company. Hexagon Capital Partners LLC increased its position in shares of ICU Medical by 162.7% during the third quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier's stock valued at $36,000 after purchasing an additional 122 shares during the period. Allworth Financial LP increased its position in shares of ICU Medical by 100.0% during the third quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier's stock valued at $36,000 after purchasing an additional 100 shares during the period. Innealta Capital LLC bought a new stake in shares of ICU Medical during the second quarter valued at approximately $32,000. Motco bought a new stake in shares of ICU Medical during the first quarter valued at approximately $29,000. Finally, Venturi Wealth Management LLC increased its position in shares of ICU Medical by 1,510.0% during the third quarter. Venturi Wealth Management LLC now owns 322 shares of the medical instruments supplier's stock valued at $59,000 after purchasing an additional 302 shares during the period. 96.10% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ICUI. Raymond James boosted their target price on ICU Medical from $158.00 to $190.00 and gave the stock an "outperform" rating in a report on Thursday, September 12th. KeyCorp boosted their target price on ICU Medical from $147.00 to $198.00 and gave the stock an "overweight" rating in a report on Tuesday, October 15th. StockNews.com upgraded ICU Medical from a "hold" rating to a "buy" rating in a report on Thursday, September 12th. Needham & Company LLC reiterated a "hold" rating on shares of ICU Medical in a report on Thursday, October 10th. Finally, Jefferies Financial Group began coverage on ICU Medical in a report on Monday, October 14th. They set a "hold" rating and a $183.00 price target for the company. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $170.25.

Insider Buying and Selling at ICU Medical

In other ICU Medical news, VP Daniel Woolson sold 2,502 shares of the company's stock in a transaction on Friday, August 30th. The stock was sold at an average price of $163.22, for a total value of $408,376.44. Following the sale, the vice president now directly owns 13,107 shares in the company, valued at $2,139,324.54. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of the company's stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $163.46, for a total value of $1,961,520.00. Following the sale, the chief executive officer now directly owns 104,593 shares in the company, valued at $17,096,771.78. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Daniel Woolson sold 2,502 shares of the company's stock in a transaction on Friday, August 30th. The shares were sold at an average price of $163.22, for a total value of $408,376.44. Following the completion of the sale, the vice president now owns 13,107 shares in the company, valued at $2,139,324.54. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 50,502 shares of company stock worth $8,445,976 over the last three months. Company insiders own 6.70% of the company's stock.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey's 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2025. Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey's 5th Congressional District. He declared candidacy for the 2024 election. Gottheimer was first elected to the House in 2016. Prior to his election, Gottheimer worked for Microsoft, the Federal Communications Commission, and for the administration of President Bill Clinton (D). Click here for more information about Gottheimer's career. Gottheimer serves on the House Financial Services Committee, where is a member of three subcommittees. For more on Gottheimer's committee assignments, click here. Gottheimer became a co-chair of the Problem Solvers Caucus in February 2017. Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.